Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study
Ann Rheum Dis
.
2023 Jan;82(1):e3.
doi: 10.1136/annrheumdis-2020-219265.
Epub 2020 Oct 30.
Authors
Sergey Moiseev
1
,
Sergey Avdeev
2
,
Ekaterina Tao
3
,
Michail Brovko
3
,
Nikolay Bulanov
3
,
Anastasiia Zykova
4
,
Larisa Akulkina
3
,
Irina Smirnova
3
,
Victor Fomin
5
Affiliations
1
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation avt420034@yahoo.com.
2
Clinic of Pulmonology, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
3
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
4
Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russian Federation.
5
Vinogradov Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.
PMID:
33127662
DOI:
10.1136/annrheumdis-2020-219265
No abstract available
Keywords:
antirheumatic agents; autoimmunity; inflammation.
Publication types
Letter
Comment
MeSH terms
COVID-19 Drug Treatment
COVID-19*
Humans
Intensive Care Units
Retrospective Studies
Substances
tocilizumab